Synergistic combinatorial antihyperlipidemic study of selected natural antioxidants; modulatory effects on lipid profile and endogenous antioxidants

Peer Abdul Hannan, Jamshaid Ali Khan*, Irfan Ullah and Safi Ullah

Abstract

Background: Hyperlipidemia, a major pathological condition associated with disrupted lipid levels and physiological redox homeostasis. The excessive release of reactive oxygen species (ROS) leads to enhanced lipid peroxidation, aggravated atherosclerosis and oxidative stress. Integration of natural antioxidant blends in alone or with conventional treatments can alleviate these issues synergistically contributing least side effects. Published literature reported the efficacy of natural antioxidants as individual and in combinations in various conditions but less data is available on their evaluation in low dose ratio blends particularly in hypercholesterolemic diet.

Methods: Antihyperlipidemic effects of selected natural antioxidants; the phenolic oligomeric proanthocyanidins (OPC) and pterostilbene (PT) with niacin (NA) were investigated in current study. Their effects on lipid profile, lipid peroxidation and their aptitude to establish redox state between oxidants and antioxidants in body were evaluated in high cholesterol diet fed animal model. Male albino rabbits (n = 6) weighing 1.2–1.6 kg, supplemented with high cholesterol diet (400 mg/kg) for 12 weeks were used in the experiment. Antioxidants were administered individual high (100 mg/kg) and in low dose combinations (total dose = 100 mg/kg). Student’s t test and one way analysis of variance (ANOVA) followed by Dunnet’s test were used as statistical tools for evaluation.

Results: The results showed synergistic effects of low dose antioxidant blends. Therapies retarded elevation in blood lipid levels, lipid peroxidation and blood antioxidant depletion and consequently contributed in reestablishing redox homeostasis. The LDL/HDL ratio and atherogenic index were suppressed significantly in blend therapies with maximum effects of 59.3 and 25 % (p >0.001) observed in 50:30:20 ratios of OPC, NA and PT, compared to individual therapies 37 and 18 % max respectively. Moreover the results were also in close proximity with the statin therapy (52.66, 26.28 %).

Conclusion: This study provides an evidence for natural antioxidants blends superiority over individual therapy in chronic diseases like hyperlipidemia. Such therapies in human equivalent doses can help in mitigating chronic illnesses in general populations.

Keywords: Hyperlipidemia, Atherosclerosis, Redox homeostasis, Synergism, Lipid peroxidation
Background
Hyperlipidemia is a major pathological condition associated with mortality and disability in both developed and developing countries [1]. Chronic diseases like obesity, diabetes, atherosclerosis, coronary heart disease are closely interconnected to hyperlipidemia. Intake of high fat diet and lack of exercise are the major causes of hyperlipidemia. In normal metabolic processes; reactive oxygen species (ROS) are released as byproducts. They act not only as essential part of immunity, in signaling transduction and other vital processes but also responsible for detrimental effects through peroxidation of lipid bilayers. Therefore to maintain the physiological redox environment, the excess radicals are get scavenged by blood antioxidants [2]. Hyperlipidemia disrupts this redox balance and cause abnormal and uncontrolled release of free radicals resulting in accelerated atherogenic events developing a state of oxidative stress [3]. Endothelial cell membrane and unsaturated lipids including trans fatty acids is the main content of circulating low density lipoproteins (LDL) are the most vulnerable sites for free radical attack. Their oxidation leads to severe endothelial cell injury and atherosclerosis [4–6]. The saturated fats do not undergo lipid peroxidation therefore has no direct effect on oxidative stress biomarkers [7]. However when esterified with poly unsaturated fatty acids (PUFA), which is the readily oxidizable content, the esters gets oxidized initiating the inflammation and atherogenesis [8]. The antioxidants present in blood and organs including glutathione, ascorbic acid, α-tocopherol fights against the progression of oxidative stress to regain the redox homeostasis but gets depleted in chronic conditions like hyperlipidemia [9, 10]. In such circumstances interventions with natural antioxidants supplements were found effective in normalizing lipid profile and blood antioxidant levels as reported previously [4, 11, 12]. Research data is well documented and supported the notion regarding their efficacies in chronic pathologies such as hyperlipidemia [13–16].

Natural antioxidants were evaluated in individual and in combinations for lipid lowering and free radical scavenging properties and were found effective in depressing the disease progression [14–22]. In current study natural antioxidants including oligomeric proanthocyanidins (hydrophilic), pterostilbene (lipophilic) and niacin were evaluated for extent of synergism by observing their effects in both individual and blended therapies.

Oligomeric proanthocyanidins (OPC) is a polyphenolic compound belongs to flavonoids class, widely distributed in plants and posses potent antioxidant [23] and lipid modulatory effects [24, 25]. Pterostilbene (PT) a phytalexin, analogue of resvaretrol belong to the class stilbenes, found in grapes majorly and possess antihyperlipidemic, antidiabetic, antioxidant properties [26]. It is also a potent activator of fatty acid metabolism [27]. Niacin or nicotinic acid (NA) found in natural products and well known for its antihyperlipidemic and antioxidant activities [28–30]. To best of our knowledge less data was extracted about lipid lowering effect of pterostilbene with OPC and NA in blend therapies especially low doses in orally fed high cholesterol diet models. The current study was designed to investigate the extent of synergism of selected hydrophilic/lipophilic natural antioxidants in assorted combination therapies in “hyperlipidemic animal model” using rabbits. Antioxidants were administered in individual and in low dose combination ratios. Atorvastatin was used as a standard for comparative analysis. Effects were evaluated against negative control group kept on cholesterol only. Serum lipid profiles were analyzed at predetermined intervals using standard kit method, while blood antioxidants and lipid peroxidation were evaluated using HPLC methods [31, 32].

Results and discussions
Acute rise in lipid profiles were observed in rabbits administered with cholesterol for 2 weeks compared to healthy group. Almost two to four time rise was observed in every parameter. Student’s t test was applied to evaluate the difference statistically. Lipid profiles are calculated as mean ± SEM (n = 6) along with p-values in Table 1.

Effect of exogenous antioxidant therapy on serum lipid profile
Single drug therapies showed significant effects in reducing lipid levels, confirmed by LDL/HDL ratio and atherogenic index (AI). The OPC, NA and PT maintained LDL/HDL ratios by 19.49 ± 0.87 (p <0.001), 20.26 ± 0.94 (p <0.001) and 19.19 ± 0.91 (p <0.01) and AI values 0.893 ± 0.033 (p <0.01), 0.896 ± 0.053 (p <0.01), 0.971 ± 0.073 (p <0.05) respectively. The atorvastatin therapy showed 14.0 ± 0.99 (p <0.001) and 0.785 ± 0.061 (p <0.001) compared to disease control 30.50 ± 0.69, 1.096 ± 0.040. In combination therapies the results were even more significant and synergism were observed by improving blood lipid profile depending on dose ratio in particular combination. Among combinations of OPC with NA the 70:30 ratio delivered significant effects by suppressing LDL/HDL ratio to 15.36 ± 0.98 (p <0.001) while differ nonsignificantly from other two ratios 16.77 ± 0.69 (p <0.001) and 17.33 ± 0.75 (p <0.001). AI was significantly reduced to 0.843 ± 0.041 (p <0.001), 0.837 ± 0.045 (p <0.001) and 0.887 ± 0.037 (p <0.01) in 70:30, 30:70 and 50:50 respectively. Similarly in OPC with PT combinations all the ratios provided significant effects compared to disease control but no significant differences were observed between the groups. The LDL/HDL and AI were 14.60 ± 0.98 (p <0.001) and 0.851 ± 0.041

Background
Hyperlipidemia is a major pathological condition associated with mortality and disability in both developed and developing countries [1]. Chronic diseases like obesity, diabetes, atherosclerosis, coronary heart disease are closely interconnected to hyperlipidemia. Intake of high fat diet and lack of exercise are the major causes of hyperlipidemia. In normal metabolic processes; reactive oxygen species (ROS) are released as byproducts. They act not only as essential part of immunity, in signaling transduction and other vital processes but also responsible for detrimental effects through peroxidation of lipid bilayers. Therefore to maintain the physiological redox environment, the excess radicals are get scavenged by blood antioxidants [2]. Hyperlipidemia disrupts this redox balance and cause abnormal and uncontrolled release of free radicals resulting in accelerated atherogenic events developing a state of oxidative stress [3]. Endothelial cell membrane and unsaturated lipids including trans fatty acids is the main content of circulating low density lipoproteins (LDL) are the most vulnerable sites for free radical attack. Their oxidation leads to severe endothelial cell injury and atherosclerosis [4–6]. The saturated fats do not undergo lipid peroxidation therefore has no direct effect on oxidative stress biomarkers [7]. However when esterified with poly unsaturated fatty acids (PUFA), which is the readily oxidizable content, the esters gets oxidized initiating the inflammation and atherogenesis [8]. The antioxidants present in blood and organs including glutathione, ascorbic acid, α-tocopherol fights against the progression of oxidative stress to regain the redox homeostasis but gets depleted in chronic conditions like hyperlipidemia [9, 10]. In such circumstances interventions with natural antioxidants supplements were found effective in normalizing lipid profile and blood antioxidant levels as reported previously [4, 11, 12]. Research data is well documented and supported the notion regarding their efficacies in chronic pathologies such as hyperlipidemia [13–16].

Natural antioxidants were evaluated in individual and in combinations for lipid lowering and free radical scavenging properties and were found effective in depressing the disease progression [14–22]. In current study natural antioxidants including oligomeric proanthocyanidins (hydrophilic), pterostilbene (lipophilic) and niacin were evaluated for extent of synergism by observing their effects in both individual and blended therapies.

Oligomeric proanthocyanidins (OPC) is a polyphenolic compound belongs to flavonoids class, widely distributed in plants and posses potent antioxidant [23] and lipid modulatory effects [24, 25]. Pterostilbene (PT) a phytalexin, analogue of resvaretrol belong to the class stilbenes, found in grapes majorly and possess antihyperlipidemic, antidiabetic, antioxidant properties [26]. It is also a potent activator of fatty acid metabolism [27]. Niacin or nicotinic acid (NA) found in natural products and well known for its antihyperlipidemic and antioxidant activities [28–30]. To best of our knowledge less data was extracted about lipid lowering effect of pterostilbene with OPC and NA in blend therapies especially low doses in orally fed high cholesterol diet models. The current study was designed to investigate the extent of synergism of selected hydrophilic/lipophilic natural antioxidants in assorted combination therapies in “hyperlipidemic animal model” using rabbits. Antioxidants were administered in individual and in low dose combination ratios. Atorvastatin was used as a standard for comparative analysis. Effects were evaluated against negative control group kept on cholesterol only. Serum lipid profiles were analyzed at predetermined intervals using standard kit method, while blood antioxidants and lipid peroxidation were evaluated using HPLC methods [31, 32].

Results and discussions
Acute rise in lipid profiles were observed in rabbits administered with cholesterol for 2 weeks compared to healthy group. Almost two to four time rise was observed in every parameter. Student’s t test was applied to evaluate the difference statistically. Lipid profiles are calculated as mean ± SEM (n = 6) along with p-values in Table 1.

Effect of exogenous antioxidant therapy on serum lipid profile
Single drug therapies showed significant effects in reducing lipid levels, confirmed by LDL/HDL ratio and atherogenic index (AI). The OPC, NA and PT maintained LDL/HDL ratios by 19.49 ± 0.87 (p <0.001), 20.26 ± 0.94 (p <0.001) and 19.19 ± 0.91 (p <0.01) and AI values 0.893 ± 0.033 (p <0.01), 0.896 ± 0.053 (p <0.01), 0.971 ± 0.073 (p <0.05) respectively. The atorvastatin therapy showed 14.0 ± 0.99 (p <0.001) and 0.785 ± 0.061 (p <0.001) compared to disease control 30.50 ± 0.69, 1.096 ± 0.040. In combination therapies the results were even more significant and synergism were observed by improving blood lipid profile depending on dose ratio in particular combination. Among combinations of OPC with NA the 70:30 ratio delivered significant effects by suppressing LDL/HDL ratio to 15.36 ± 0.98 (p <0.001) while differ nonsignificantly from other two ratios 16.77 ± 0.69 (p <0.001) and 17.33 ± 0.75 (p <0.001). AI was significantly reduced to 0.843 ± 0.041 (p <0.001), 0.837 ± 0.045 (p <0.001) and 0.887 ± 0.037 (p <0.01) in 70:30, 30:70 and 50:50 respectively. Similarly in OPC with PT combinations all the ratios provided significant effects compared to disease control but no significant differences were observed between the groups. The LDL/HDL and AI were 14.60 ± 0.98 (p <0.001) and 0.851 ± 0.041
Effects of natural antioxidants therapies on blood endogenous antioxidants

Effects of natural antioxidants therapies on blood antioxidants were evaluated by quantifying their levels in serum samples. They were quantified in normal, disease control, statin group, individual therapies groups, combination groups in each two drug ratios with optimum effects and all three drugs combinational therapies. Results showed initial rise in various antioxidants after 2 weeks of cholesterol dosing, presumably due to the over activation of antioxidant enzymes the catalase, glutathione peroxidase, superoxide dismutase and others; accelerating the production of GSH against peroxides radicals. Only NAC was found in reduced concentrations.

Significant up-regulation was observed in levels of methionine, GSH and NAC upto 35.08± 1.60, 3.82± 0.47 and 4.21± 0.425 μmol/L (p <0.001 each) respectively in combination therapies compared to disease control 19.30± 1.18, 3.01± 0.28 and 3.73± 0.412 μmol/L. Although in individual therapies the raised levels of methionine, GSH and NAC (24.73± 1.04 μmol/L (p <0.05), 3.38± 0.42 μmol/L (p <0.01) and 3.86± 0.404 μmol/L (p <0.05)) were less significant compared to combination therapies. The all-trans retinoic acid showed opposite results and increased parallel with the lipid levels from 1.80± 0.10 μmol/L (blank control) to 4.48± 0.24 μmol/L (disease control) while in treatment groups its elevation was retarded down to 3.26± 0.12 μmol/L (p <0.001) max; observed on 70:30 ratio of OPC and PT.

The improvement in GSH/GSSG ratios was significant in OPC (2.83± 0.065) (p <0.01) among individual therapies and more in combinational therapies ranging 2.51± 0.092 to 3.40± 0.097 (p <0.001), compared to disease control 2.12± 0.058. Homocysteine level was significantly controlled down to 10.09± 1.39 μmol/L (p <0.01), although nonsignificant variations were observed among treatment groups. Almost half of groups delivered non-significant effects on ascorbic acid levels with maximum effect of 5.29± 0.51 μmol/L (p <0.001) observed in 50:30:20 ratio of OPC, NA and PT which suppressed LDL/HDL ratio by 59.3 % and AI by 25 % (p <0.001) comparable with the statin outcome 52.66, 26.28 % (p <0.001) respectively. Though there were minor differences among the groups but differ significantly from the disease control. The high dose single drug therapies suppressed LDL/HDL by 37 % and AI by 18.5 % maximum, which are much less as compared to low dose blend therapies confirmed the superiority of combinational therapies. Lipid profiles in mean ± SEM and %change in blood lipids at 95 % confidence interval are summarized in Tables 2 and 3.

Effect of exogenous antioxidant therapy on blood endogenous antioxidants

Enhanced lipid peroxidation and endogenous antioxidant depletion are undoubtedly associated with hyperlipidemia [10, 34, 35]. This leads to a number of atherogenic effects including plaque formation in the vessel lumen and accelerating foam cells formation within vessel walls [36]. Natural antioxidants including those used in current study were applied in many chronic pathological conditions such as hyperlipidemia to prevent peroxidation, endogenous antioxidant depletion and suppression of oxidative stress.
progression [37, 38]. Natural antioxidants specially polyphenols present efficacy up to certain level [39, 40] above which they were found ineffective or as pro-oxidant by revoking their own beneficial effects. Similar effects were observed in ascorbic acid interventions, preventing pro-oxidant effects of LDL-associated apolipoprotein B when gets oxidized in blood [41]. Same initiative was considered here that in place of using bulk dose individual therapies, the low dose combination therapies might provide superior results. Since each candidate delivers different antiperoxidative mechanisms preventing depletion of antioxidant cofactors. OPC act by up-regulating peroxisome proliferator-activated receptor (PPAR) [26]. NA by preventing lipid mobilization from tissues and consequent rise in plasma TG and free fatty acids (FFA) levels [29, 30, 42]. It also increases the plasma HDL levels and acts as antioxidant when transformed into nicotinamide [28, 43–45]. To our knowledge no such extensive study was performed in hyperlipidemia to demonstrate dose dependant effect invivo in combinational therapies of currently used antioxidants. Our study revealed to be parallel with previous data available on other disease conditions confirming the hypothesis of enhancing efficacy of concurrently administered natural antioxidants. Synergism at low

Table 2 Blood lipid profile of various groups after 12 weeks of study duration

| GROUP | TC value (mg dl$^{-1}$) ± SEM | LDL-C value (mg dl$^{-1}$) ± SEM | HDL-C value (mg dl$^{-1}$) ± SEM | TG value (mg dl$^{-1}$) ± SEM | VLDL-C (mg dl$^{-1}$) Value ± SEM | LDL/HDL ratio ± SEM | Atherogenic index ± SEM |
|-------|-----------------------------|---------------------------------|---------------------------------|-------------------------------|-------------------------------|-------------------|------------------------|
| 1 Blank Control | 105 ± 5.013 | 58.75 ± 18.25 | 30.65 ± 1.74 | 78 ± 3.527 | 3545 ± 3.074 | 1.971 ± 0.56 | 0.406 ± 0.037 |
| 2 Disease Control | 946 ± 38.53 | 848.8 ± 34.19 | 27.83 ± 0.82 | 347 ± 10.04 | 157.7 ± 2.29 | 30.50 ± 0.69 | 1.096 ± 0.040 |
| 3 Atorvastatin | *** | *** | *** | *** | *** | *** | *** |
| 4 Proanthocyanidins (OPC) | 625 ± 17.42 | 539.65 ± 15.01 | 37.35 ± 1.72 | 240 ± 5.49 | 109.1 ± 3.35 | 14.45 ± 0.99 | 0.808 ± 0.061 |
| 5 Nicotinic acid (NA) | 733 ± 21.42 | 647.8 ± 19.34 | 33.24 ± 2.09 | 260 ± 9.10 | 118.2 ± 2.09 | 19.49 ± 0.87 | 0.893 ± 0.033 |
| 6 Pterostilbene (PT) | 806 ± 16.51 | 715.1 ± 19.87 | 35.29 ± 1.85 | 278 ± 8.66 | 126.4 ± 4.79 | 20.26 ± 0.94 | 0.896 ± 0.053 |
| 7 OPC : NA (30:70) | 698 ± 14.19 | 607.16 ± 14.45 | 31.64 ± 3.03 | 296 ± 3.64 | 134.5 ± 6.30 | 19.19 ± 0.91 | 0.971 ± 0.073 |
| 8 OPC : NA (50:50) | 725 ± 15.92 | 635.1 ± 14.62 | 37.86 ± 1.88 | 260 ± 6.26 | 118.2 ± 3.93 | 16.77 ± 0.69 | 0.837 ± 0.045 |
| 9 OPC : NA (70:30) | 704 ± 13.15 | 614.0 ± 12.58 | 35.42 ± 1.36 | 273 ± 8.68 | 124.1 ± 3.76 | 17.33 ± 0.75 | 0.887 ± 0.037 |
| 10 OPC : PT (30:70) | 642 ± 13.31 | 555.4 ± 11.65 | 36.16 ± 2.13 | 252 ± 8.54 | 114.5 ± 3.38 | 15.36 ± 0.98 | 0.843 ± 0.041 |
| 11 OPC : PT (50:50) | 598 ± 14.01 | 507.8 ± 10.38 | 33.42 ± 1.68 | 284 ± 3.81 | 129.1 ± 4.17 | 15.19 ± 0.42 | 0.929 ± 0.057 |
| 12 OPC : PT (70:30) | 642 ± 15.60 | 553.5 ± 14.66 | 33.89 ± 2.12 | 273 ± 8.68 | 124.1 ± 3.76 | 16.33 ± 0.75 | 0.906 ± 0.037 |
| 13 NA : PT (30:70) | 608 ± 15.06 | 518.0 ± 12.37 | 35.47 ± 2.16 | 252 ± 8.95 | 114.5 ± 3.38 | 14.60 ± 0.98 | 0.851 ± 0.041 |
| 14 NA : PT (50:50) | 615 ± 15.02 | 526.2 ± 9.57 | 33.41 ± 1.61 | 277 ± 11.1 | 125.9 ± 3.04 | 15.75 ± 0.53 | 0.919 ± 0.037 |
| 15 NA : PT (70:30) | 646 ± 13.97 | 555.4 ± 12.30 | 36.63 ± 1.54 | 270 ± 7.07 | 122.7 ± 4.34 | 15.16 ± 0.84 | 0.868 ± 0.037 |
| 16 OPC : NA : PT (50:30:20) | 563 ± 13.31 | 474.2 ± 11.55 | 38.20 ± 1.89 | 253 ± 6.65 | 115.0 ± 3.04 | 12.41 ± 0.72 | 0.821 ± 0.041 |
| 17 OPC : NA : PT (50:20:30) | 572 ± 13.15 | 482.67 ± 8.29 | 37.53 ± 1.34 | 259 ± 9.46 | 120.5 ± 5.08 | 12.86 ± 0.78 | 0.839 ± 0.037 |
| 18 OPC : NA : PT (20:50:30) | 588 ± 11.73 | 497.32 ± 13.06 | 38.68 ± 2.37 | 260 ± 2.81 | 118.2 ± 2.83 | 12.86 ± 1.17 | 0.827 ± 0.029 |

For a group of six animals, the lipid profiles were calculated as mean ± SEM. Treatment groups were compared with the disease control using ANOVA followed by Dunnet’s test (*p <0.05, **p <0.01, ***p <0.001)
Table 3: Mean percent change in lipid profile after 12 weeks in each treatment group

| GROUP          | TC value (95 % CI) | LDL-C value (95 % CI) | HDL-C value (95 % CI) | TG value (95 % CI) | VLDL-C (95 % CI) | LDL/HDL (95 % CI) | Atherogenic index (95 % CI) |
|----------------|--------------------|-----------------------|-----------------------|-------------------|-----------------|-----------------|-------------------------|
| 1 Atorvastatin | −34.0 (−36.43, −31.57) | −36.42 (−39.00, −33.80) | 34.20 (29.78, 38.62) | −30.80 (−32.74, −28.86) | −30.80 (−33.58, −28.02) | −30.80 (−32.65, −27.76) | −26.28 (−31.97, −20.59) |
| 2 Proanthocyanidins (OPC) | −22.50 (−24.19, −20.81) | −23.68 (−25.50, −21.86) | 19.44 (16.30, 22.58) | −25.07 (−27.33, −22.81) | −25.05 (−26.18, −23.92) | −30.69 (−40.21, −31.97) | −18.52 (−20.26, −16.78) |
| 3 Nicotinic acid (NA) | −14.90 (−15.69, −14.11) | −15.75 (−16.87, −14.63) | 26.8 (23.19, 30.41) | −19.88 (−21.48, −18.28) | −20.95 (−21.78, −17.92) | −33.57 (−37.57, −29.57) | −18.25 (−21.03, −15.47) |
| 4 Pterostilbene (PT) | −26.22 (−27.59, −24.85) | −28.47 (−30.51, −26.43) | 13.69 (10.32, 17.06) | −14.7 (−15.16, −14.24) | −14.71 (−16.48, −12.94) | −37.08 (−41.58, −32.58) | −11.4 (−13.12, −9.67) |
| 5 OPC : NA 30:70 | −23.36 (−24.68, −22.04) | −25.18 (−26.67, −23.69) | 36.0 (31.41, 40.59) | −25.07 (−26.62, −23.52) | −25.05 (−27.19, −22.91) | −45.02 (−49.82, −40.22) | −23.63 (−26.88, −20.38) |
| 6 OPC : NA 50:50 | −25.58 (−26.81, −24.35) | −27.66 (−29.11, −26.21) | 27.27 (24.54, 30.00) | −21.32 (−23.07, −19.57) | −21.31 (−22.97, −19.65) | −43.2 (−48.02, −38.38) | −19.07 (−21.10, −17.04) |
| 7 OPC : NA 70:30 | −32.13 (−33.84, −30.42) | −34.57 (−37.89, −31.25) | 29.9 (25.39, 34.41) | −27.4 (−29.81, −24.99) | −27.4 (−29.48, −25.32) | −49.64 (−57.83, −41.45) | −23.08 (−25.94, −20.22) |
| 8 OPC : PT 30:70 | −36.79 (−39.00, −34.58) | −40.17 (−42.27, −38.07) | 20.09 (17.50, 22.68) | −18.16 (−18.79, −17.53) | −18.13 (−19.63, −16.63) | −50.2 (−53.74, −46.66) | −15.24 (−17.65, −12.83) |
| 9 OPC : PT 50:50 | −32.13 (−34.13, −30.13) | −34.97 (−37.36, −32.58) | 27.27 (22.98, 31.56) | −21.33 (−23.07, −19.59) | −21.31 (−22.97, −19.65) | −48.9 (−54.96, −42.84) | −19.07 (−21.11, −17.03) |
| 10 OPC : PT 70:30 | −35.73 (−38.01, −33.45) | −38.97 (−41.34, −36.60) | 27.45 (23.16, 31.74) | −27.38 (−29.88, −24.88) | −27.39 (−29.47, −25.31) | −49.64 (−57.82, −41.46) | −22.35 (−25.11, −19.59) |
| 11 NA : PT 30:70 | −34.99 (−37.18, −32.80) | −38.0 (−39.77, −36.23) | 20.05 (17.56, 17.56) | −20.17 (−22.24, −18.10) | −20.16 (−21.41, −18.91) | −48.36 (−52.55, −44.17) | −16.15 (−17.81, −14.49) |
| 12 NA : PT 50:50 | −31.71 (−33.47, −29.95) | −34.57 (−36.54, −32.60) | 31.62 (28.20, 35.04) | −22.19 (−23.68, −20.70) | −22.19 (−24.20, −20.18) | −50.30 (−57.47, −43.13) | −20.8 (−23.07, −18.53) |
| 13 NA : PT 70:30 | −30.34 (−29.62, −26.82) | −33.13 (−32.21, −29.33) | 34.53 (29.17, 39.89) | −22.2 (−23.45, −20.95) | −22.2 (−23.99, −20.41) | −50.30 (−55.64, −41.48) | −21.72 (−25.18, −18.26) |
| 14 OPC : NA : PT 50:30:20 | −40.49 (−42.95, −38.03) | −44.1 (−46.86, −41.34) | 37.26 (32.61, 41.91) | −27.09 (−28.92, −25.26) | −27.08 (−28.92, −25.24) | −59.30 (−68.18, −50.42) | −25.09 (−28.30, −21.88) |
| 15 OPC : NA : PT 50:20:30 | −39.53 (−41.86, −37.20) | −43.13 (−45.10, −41.28) | 32.5 (29.48, 35.52) | −25.36 (−27.52, −23.20) | −23.59 (−26.15, −21.03) | −57.84 (−66.56, −49.12) | −23.45 (−25.85, −21.05) |
| 16 OPC : NA : PT 20:50:30 | −37.80 (−39.74, −35.86) | −41.4 (−44.20, −38.60) | 38.99 (32.84, 45.14) | −25.07 (−27.56, −24.38) | −25.05 (−26.59, −23.51) | −57.80 (−68.45, −47.15) | −24.50 (−26.67, −22.33) |

Data is presented as mean percent change from the disease control at 95 % confidence interval
The lipophilic antioxidant α-tocopherol, a major antioxidant in LDL prevents peroxidation by getting oxidized by free radicals and administering it alone especially in chronic illnesses will increase cardiovascular risk rather than decreasing it. Administration with exogenous antioxidants in LDL prevents peroxidation by getting oxidized – lipid profile and blood antioxidants in hyperlipidemic condition [39, 46–48]. The lipophilic antioxidant α-tocopherol, a major antioxidant in LDL prevents peroxidation by getting oxidized by free radicals and administering it alone especially in chronic illnesses will increase cardiovascular risk rather than decreasing it. Administration with exogenous antioxidants was found helpful in reducing the chances of antioxidants to become pro-oxidant. The reduction in LDL/HDL ratio and AI validate the positive outcome of multi antioxidant therapies on lipid profile and blood antioxidants in hyperlipidemic condition [39, 46–48].

The lipophilic antioxidant α-tocopherol, a major antioxidant in LDL prevents peroxidation by getting oxidized by free radicals and administering it alone especially in chronic illnesses will increase cardiovascular risk rather than decreasing it. Administration with exogenous antioxidants was found helpful in reducing the chances of antioxidants to become pro-oxidant. The reduction in LDL/HDL ratio and AI validate the positive outcome of multi antioxidant therapies on lipid profile and blood antioxidants in hyperlipidemic condition [39, 46–48].

### Table 4 Quantification of water soluble endogenous antioxidants levels in various test groups

| Groups                  | Cystine (μmol/L) | Cysteine (μmol/L) | Homo-cysteine (μmol/L) | Methionine (μmol/L) | Glutathione reduced (μmol/L) | Glutathione oxidized (μmol/L) | GSH/GSSG | N-acetyl cysteine (μmol/L) |
|-------------------------|------------------|-------------------|------------------------|--------------------|-----------------------------|-----------------------------|----------|---------------------------|
| Baseline                | 52.95 ± 1.68      | 13.66 ± 0.87      | 8.72 ± 0.87            | 38.05 ± 1.55       | 3.75 ± 0.384                 | 0.87 ± 0.037                 | 4.42 ± 0.085 | 4.57 ± 0.457               |
| After 2 weeks of CHO-dosing | 93.35 ± 3.81    | 14.31 ± 1.09      | 9.08 ± 0.96            | 34.97 ± 1.77       | 4.13 ± 0.245                 | 1.25 ± 0.041                 | 3.26 ± 0.067 | 4.38 ± 0.441               |

### Observed changes after 90 days of treatment in groups

| Groups                  | Cystine (μmol/L) | Cysteine (μmol/L) | Homo-cysteine (μmol/L) | Methionine (μmol/L) | Glutathione reduced (μmol/L) | Glutathione oxidized (μmol/L) | GSH/GSSG | N-acetyl cysteine (μmol/L) |
|-------------------------|------------------|-------------------|------------------------|--------------------|-----------------------------|-----------------------------|----------|---------------------------|
| Blank control           | 60.35 ± 1.68      | 14.70 ± 1.14      | 8.56 ± 1.13            | 36.20 ± 1.48       | 3.75 ± 0.384                 | 0.87 ± 0.037                 | 4.42 ± 0.085 | 4.57 ± 0.457               |
| Disease control         | 120.8 ± 1.44      | 42.36 ± 2.62      | 14.78 ± 1.49           | 39.32 ± 1.88       | 3.78 ± 0.41                  | 0.92 ± 0.029                 | 4.18 ± 0.12 | 4.49 ± 0.249               |
| Atorvastatin            | 79.59 ± 1.45      | 36.70 ± 2.29      | 12.09 ± 1.63           | 19.85 ± 1.26       | 3.38 ± 0.38                  | 1.35 ± 0.057                 | 2.55 ± 0.081 | 3.83 ± 0.396               |
| Proanthocyanidins (OPC) | 84.36 ± 3.39      | 34.84 ± 2.13      | 11.44 ± 1.06           | 24.73 ± 1.04       | 3.38 ± 0.42                  | 1.20 ± 0.049                 | 2.83 ± 0.065 | 3.86 ± 0.404               |
| Nicotinic acid (NA)     | 101.35 ± 3.89     | 38.94 ± 1.95      | 12.85 ± 1.45           | 20.51 ± 0.68       | 3.32 ± 0.41                  | 1.24 ± 0.045                 | 2.65 ± 0.090 | 3.68 ± 0.416               |
| Pterostilbene (PT)      | 98.81 ± 5.42      | 36.75 ± 2.13      | 11.76 ± 1.12           | 21.88 ± 1.16       | 3.20 ± 0.42                  | 1.29 ± 0.041                 | 2.51 ± 0.092 | 3.80 ± 0.351               |
| OPC: NA (70:30)         | 87.23 ± 2.94      | 33.51 ± 1.41      | 10.87 ± 1.21           | 29.83 ± 1.04       | 3.60 ± 0.39                  | 1.23 ± 0.045                 | 2.90 ± 0.14  | 3.77 ± 0.306               |
| OPC: PT (70:30)         | 83.77 ± 4.53      | 31.42 ± 2.37      | 11.34 ± 1.27           | 26.42 ± 0.87       | 3.55 ± 0.45                  | 1.19 ± 0.037                 | 2.97 ± 0.082 | 3.95 ± 0.416               |
| NA: PT (70:30)          | 94.52 ± 3.39      | 31.88 ± 1.88      | 11.92 ± 1.06           | 30.12 ± 1.32       | 3.57 ± 0.36                  | 1.28 ± 0.053                 | 2.78 ± 0.15  | 3.74 ± 0.339               |
| OPC: NA: PT (50:30:20)  | 77.44 ± 3.87      | 29.72 ± 1.46      | 10.09 ± 1.39           | 35.08 ± 1.60       | 3.82 ± 0.47                  | 1.12 ± 0.057                 | 3.40 ± 0.097 | 4.14 ± 0.449               |
| OPC: NA: PT (50:20:30)  | 79.75 ± 3.89      | 30.45 ± 1.59      | 10.64 ± 1.13           | 28.58 ± 0.84       | 3.77 ± 0.48                  | 1.17 ± 0.041                 | 3.25 ± 0.069 | 4.21 ± 0.425               |
| OPC: NA: PT (20:50:30)  | 85.80 ± 3.05      | 29.35 ± 1.93      | 11.17 ± 1.02           | 25.65 ± 1.23       | 3.59 ± 0.45                  | 1.14 ± 0.049                 | 3.15 ± 0.083 | 4.08 ± 0.400               |

For a group of six animals, the lipid profiles were calculated as mean ± SEM. Treatment groups were compared with the disease control using ANOVA followed by Dunnet's test (*p < 0.05, **p < 0.01, ***p < 0.001)
lipid profile and improving cardiovascular health in clinical and preclinical studies [56, 57]. It acts dose dependently up to large doses but, the chances of adverse effects like hepatotoxicity [58] and hyperhomocysteinaemia [59] are also reported. However, if combined in low doses with other drugs the adverse events can be minimized along with maximized beneficial outcome. Our proposed therapies were found parallel with several other studies that utilized natural antioxidants in various cardiovascular related conditions [5, 30, 35, 57–60].

Key findings of current study is that combination therapies of natural antioxidants can provide synergistic and additive support for normalizing lipid profile and blood antioxidants in chronic pathological conditions if used below ceiling line. Assessing the serum levels of bio-compounds, the elevated levels of cystine, cysteine, homocysteine, all-trans retinoic acid and malondialdehyde validated their involvement in development of hyperlipidemia associated oxidative stress. We developed a dose rationale of selected antioxidants in combination for future use in human equivalent doses in which their efficacies can be evaluated in uncontrolled dietary habits. This will help in developing an efficacy based correlation between preclinical and clinical outcome in preventing atherosclerosis, comparable to conventional drug therapies with negligible side effects.

Conclusion
In present study hypolipidemic and endogenous antioxidant sparing effects of natural antioxidants were investigated in cholesterol fed rabbits. Results supported the assumption of synergism of natural/dietary antioxidants in combination therapies in chronic ailments. Low dose blend therapies were more effective than individual bulk doses as depicted. We recommend antioxidants in combination dose rationale for achieving maximum benefits in long term therapies.

Methods
Chemicals, drugs and reagents
Pure cholesterol (Avonchem UK) (≥99 % pure). Cholesterol kit; TC, TG and HDL (Human diagnostics GmbH Germany). Oligomeric proanthocyanidins (OPC) (Shaanxi Run-Time Bio-Technology Development Co., Ltd), pterostilbene (PT) (Shanghai Korey Pharm Co., Ltd) (≥99 %

### Table 5 Quantification of fat soluble endogenous antioxidants, ascorbic acid and malondialdehyde levels in various test groups

| Parameters (μmol/L)            | α-Tocopherol          | All-trans retinoic acid | Ascorbic acid | Malondialdehyde |
|--------------------------------|-----------------------|-------------------------|---------------|-----------------|
| Baseline                       | 18.46 ± 1.74          | 1.83 ± 0.1143           | 5.59 ± 0.58   | 3.37 ± 0.233    |
| After 2 weeks of CHO-dosing    | 17.29 ± 1.56          | 2.45 ± 0.1511           | 5.45 ± 0.67   | 4.08 ± 0.269    |

**Observed changes after 90 days of treatment in groups**

| Group                              | α-Tocopherol          | All-trans retinoic acid | Ascorbic acid | Malondialdehyde |
|------------------------------------|-----------------------|-------------------------|---------------|-----------------|
| 1 Blank control                    | 18.87 ± 1.49          | 1.80 ± 0.10             | 5.53 ± 0.72   | 3.49 ± 0.318    |
| 2 Disease control                  | 11.30 ± 1.38          | 4.48 ± 0.24             | 4.96 ± 0.59   | 5.90 ± 0.404    |
| 3 Atovasatin                       | 12.57 ± 1.20          | 3.65 ± 0.22             | 4.83 ± 0.49   | 4.11 ± 0.376    |
| 4 Proanthocyanidins (OPC)          | 14.79 ± 1.31          | 3.31 ± 0.21             | 5.06 ± 0.76   | 4.82 ± 0.425    |
| 5 Nicotinic acid (NA)              | 12.58 ± 0.98          | 3.85 ± 0.25             | 4.98 ± 0.49   | 5.01 ± 0.261    |
| 6 Pterostilbene (PT)               | 13.32 ± 1.03          | 3.44 ± 0.29             | 5.01 ± 0.72   | 4.94 ± 0.396    |
| 7 OPC: NA (70:30)                  | 14.78 ± 1.67          | 3.53 ± 0.13             | 5.17 ± 0.76   | 4.66 ± 0.379    |
| 8 OPC: PT (70:30)                  | 12.86 ± 1.47          | 3.26 ± 0.12             | 5.09 ± 0.44   | 4.35 ± 0.355    |
| 9 NA: PT (70:30)                   | 13.28 ± 1.19          | 3.57 ± 0.17             | 4.92 ± 0.46   | 4.75 ± 0.416    |
| 10 OPC: NA: PT (50:30:20)          | 13.95 ± 1.89          | 3.29 ± 0.21             | 5.29 ± 0.51   | 4.14 ± 0.400    |
| 11 OPC: NA: PT (50:20:30)          | 12.76 ± 1.78          | 3.32 ± 0.16             | 5.21 ± 0.42   | 3.96 ± 0.335    |
| 12 OPC: NA: PT (20:50:30)          | 14.40 ± 1.75          | 3.54 ± 0.15             | 5.17 ± 0.48   | 4.27 ± 0.412    |

For a group of six animals, the lipid profiles were calculated as mean ± SEM. Treatment groups were compared with the disease control using ANOVA followed by Dunnet’s test (*p <0.05, **p <0.01, ***p <0.001)
pure) and niacin (NA) (Scharlau Chemie SA) (>98 % pure).

Equipments
HPLC system (Perkin Elmer, Norwalk, USA) linked with a DECADE II Electrochemical Detector (Antec Leyden, Netherland), HPLC column Discovery HS C18 RP chromatographic column (250 mm × 4.6 mm, 5 μm; Bellefonte, USA). Lambda-25 UV/Visible spectrophotometer (Perkin Elmer). Centrifuge machine (Centurion scientific Ltd) and Incubator (Incucell Med Center GmbH Germany) were used in the analysis.

Hyperlipidemic model development and interventional protocol
Male Albino rabbits (1.2–1.6 kg body weight) were used in the experiment. The experimental protocol for our study was approved by ethical committee of Department of Pharmacy University of Peshawar under reference number: 04/EC-15/Pharm. After 7 days of acclimatization in animal house and bio assay center, hyperlipidemia was developed according to the previous reported protocol [61]. Animals were administered 400 mg/kg cholesterol suspension in 3 ml sunflower oil along with normal diet (protein, fats and fibers each up to 12 %, carbohydrates 65 % and minerals 2–5 %) for about 2 weeks and subsequent analysis of serum samples. Animal having total cholesterol level raised up to 200–250 mg/dl were selected and divided into several groups of n = 6. Three groups were treated with OPC, PT and NA individually in 100 mg/kg doses along with cholesterol doses. In 09 groups, low dose combinatorial blends of all the three drugs in 30:70, 50:50 and 70:30 ratios were administered and most effective combination in each two drug combinations was further incorporated in three drug combinations (Table 2). These blends were applied to determine possible extent of synergism of low dose therapies in comparison with individual high dose (100 mg/kg) drug therapy. Atorvastatin (1 mg/kg) was used as standard in group III [62], group I was kept at baseline (saline) and group II on cholesterol only. Duration of therapy was 3 months; the animals were allowed free access to food and water ad libitum. At the end of therapy blood samples were collected in sufficient volumes for lipid profile and chromatographic analysis.

Laboratory analysis
Plasma lipid profiling was performed on commercial kits. Base line levels were recorded and samples were taken at every 2 weeks interval after overnight fasting to evaluate the effect of therapies on blood lipid levels sequentially. Total cholesterol (TC), triglyceride (TG) and high density lipoproteins (HDL-C) were calculated enzymatically, while low density lipoproteins (LDL-C), very low density lipoproteins (VLDL-C) and atherogenic index (AI) were calculated according to the following formulae [63–65].

\[ \text{LDL-C} = \text{TC} - \text{HDL-C} - \frac{\text{TG}}{5} \]  
\[ \text{VLDL-C} = \frac{\text{TG}}{2.2} \]  
\[ \text{AI} = \log_{\text{TG}}(\text{HDL-C}) \]

Serum levels of water soluble thiol antioxidants; glutathione (GSH) its oxidized form (GSSG), GSH/GSSG ratio, cystine, cysteine (cys), Homocysteine (Hcy), methionine (meth), N-acetylcysteine (NAC) long with ascorbic acid (AA) and lipid peroxidation were determined simultaneously at the end of study using RP-HPLC- electro chemical detection (ECD) method [31]. Fat soluble antioxidants; α-tocopheryl (α-TOH) and all-trans retinol (ATR) were determined simultaneously using HPLC-UV [32].

Statistical analysis
Data analysis was performed by applying student’s t test for pair analysis and one way analysis of variance (ANOVA) followed by Dunnett’s test for comparison of lipid lowering effect in all treatment groups with respect to the disease control (with no treatment). Data is presented in mean ± standard error of mean (SEM) at level of significance p <0.05 %.

Abbreviations
AA: Ascorbic acid; AI: Atherogenic index; ANOVA: One way analysis of variance; ATR: All-trans retinol; CYP: Cytochrome; Cys: Cysteine; ECD: Electro chemical detection; FFA: Free fatty acids; GSH: Glutathione; GSSG: Glutathione disulfide; Hcy: Homocysteine; HDL: High density lipoproteins; LDL: Low density lipoproteins; Meth: Methionine; NA: Niacin; NAC: N-acetylcysteine; OPC: Oligomeric proanthocyanidins; PPAR: Peroxisome proliferator-activated receptor; PT: Pterostilbene; PUFA: Poly unsaturated fatty acids; ROS: Reactive oxygen species; TG: Triglyceride; VLDL: Very low density lipoproteins; α-TOH: α-tocopherol

Acknowledgements
We are thankful to animal house and bio assay center, and biopharmaceutics research laboratory, Department of Pharmacy, University of Peshawar for providing facilities during experiments.

Funding
No funding source contributed in current research.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Authors’ contributions
PAH was primary investigator of animal studies and responsible for husbandry, sample collection and lipid analysis. JAK was co-investigator and supervisor in whole study design and contributed in developing manuscript. HPLC studies and statistical analysis was conducted by IU. SU contributed in developing hyperlipidemic model, blood sampling and finalizing the manuscript. All the authors approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.

Ethics approval and consent to participate
The experimental protocol was approved by ethical committee of Department of Pharmacy University of Peshawar under reference number: 04/EC-15/Pharm.

Received: 26 January 2016 Accepted: 2 September 2016
Published online: 09 September 2016

References
1. Zhao R, Xiao D, Fan X, Ge Z, Wang L, Yan T, et al. Epidemiological survey of dyslipidemia in civil Aviators in China from 2006 to 2011. Int J Endocrinol. 2014;2014:1–6.
2. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell B. 2007;39(1):44–84.
3. Mohan-Kumari H, Dhale MA, Akhilender Naidu K, Vijayalakshmi G. Antioxidant effect of red moulce in hypercholesteremic Wistar male rats. Cell Biochem Funct. 2011;29(7):697–702.
4. Yu F, Gao J, Zeng Y, Liu CX. Effects of adlay seed oil on blood lipids and antioxidant capacity in hyperlipidemic rats. J Sci Food Agr. 2011;91(10):1843–8.
5. Cavia-Saiz M, Busto MD, Pilar-Izquierdo MC, Ortega N, Perez-Mateos M, Muniz P. Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: A comparative study. J Sci Food Agr. 2010;90(7):1238–44.
6. Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev. 2011;111(10):5944–72.
7. Marina A, von Frankenberg AD, Suvag S, Callahan HS, Kratz M, Richards TL, Hannan et al. Lipids in Health and Disease (2016) 15:151
8. Spiteller G. The important role of lipid peroxidation processes in aging and age dependent diseases. Mol Biotechnol. 2007;37(1):5–44.
9. Campolo J, De Maria R, Mariotti C, Tomaselio C, Parolini M, Frontali M, et al. Is the Oxidant/Antioxidant status altered in CADASIL Patients? PLoS One. 2011;6(10):e26707.
10. Andersson H, Karlson A, Blomhoff R, Raadst T, Kadi F. Plasma antioxidant responses and oxidative stress following a soccer game in elite female players. Scand J Med Sci Sport. 2010;20(4):600–6.
11. Rodrigo R, Miranda A, Vergara L. Modulation of endogenous antioxidant system by wine polyphenols in human disease. Clin Chim Acta. 2011;412(5):410–24.
12. Okuyama D, Naziroglu M, Armagan A, Demirel A, Koroglu BK, Colakoglu N, et al. Dietary vitamin C and E modulates oxidative stress induced-kidney and lens injury in diabetic aged male rats through modulating glucose homeostasis and antioxidant systems. Cell Biochem Funct. 2011;29(5):287–93.
13. Quezada H, Pajuelo D, Fernandez-Iglesias A, Diaz S, Ardevol A, Blay M, et al. Proanthocyanidins modulate triglyceride secretion by repressing the expression of long chain acyl-CoA synthetases in Caco2 intestinal cells. Food Chem. 2011;124(9):1400–4.
14. Nwosu S, Adaramoye O, Ajaiyeoba E. Oral administration of extract from Curcuma longa lowers blood glucose and attenuates alloxan-induced hyperlipidemia in diabetic rabbits. Pak J Nutr. 2009;8(5):625–30.
15. Mythri RB, Bharath SM. Curcumin: a potential neuroprotective agent in Parkinson’s disease. Curr Pharm Design. 2012;18(19):91–9.
16. Berroquii H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atherosclerotic compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis. 2009; 207(2):420–7.
17. Erejuwa OO, Sulaiman SA, Wahab MSa, Salam SKm, Salleh MSM, Gurtu S. Comparison of antioxidant effects of honey, gallicamide, metformin, and their combinations in the kidneys of streptozotocin-induced diabetic rats. Int J Mol Sci. 2011;12(1):829–43.
18. Buckert L, Labrecque J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210(2):353–61.
19. Jemai H, Ei Feki A, Sayadi S. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxan-diabetic rats. J Agr Food Chem. 2009;57(19):8798–804.
20. Hou Y, Shao W, Xiao R, Xu K, Ma Z, Johnstone BH, et al. Pu-erh tea aqueous extracts lower atherosclerotic risk factors in a rat hyperlipidemia model. Exp Gerontol. 2009;44(6):454–9.
21. Michos ED, Sibley CT, Baer JT, Blaha MJ, Blumenthal RS. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease eventreconciling the aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol. 2012;59(23):2058–64.
22. Raddino R, Della Pina P, Gavazzoni M, Gorga E, Trickett E, Regazzoni V, et al. Efficacy of a combination of natural lipid-lowering and antioxidant agents in hypercholesterolaemic patients. Nutrafoods. 2012;11(4):145–50.
23. Ozbay S, Yarar S, Aliev G, Reddy VP. The role of polyphenolic antioxidants in health, disease, and aging. Rejuvenation Res. 2010;13(6):631–43.
24. Rao J, Zhang Z, Yu H, Huang Y, Chen Z-Y. Hypcholesterolemic activity of grape seed proanthocyanidin is mediated by enhancement of bile acid excretion and up-regulation of CYP7A1. J Nutr Biochem. 2010;21(11):1134–9.
25. Blade C, Arola L, Salvador MJ. Hypolipidemic effects of proanthocyanidins and their underlying biochemical and molecular mechanisms. Mol Nutr Food Res. 2010;54(1):37–59.
26. Rimando AM, Nagmari R, Feller DR, Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor-?isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agr Food Chem. 2005;53(9):3403–7.
27. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatinol in vaccinum berries. J Agric Food Chem. 2004;52(15):4713–9.
28. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48(7):106–16.
29. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Int J Med. 2005;258(2):94–114.
30. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Nicin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202(1):68–75.
31. Hannan PA, Khan JA, Iqbal Z, Rehman WU, Rehman M, et al. Simultaneous determination of endogenous antioxidants and malondialdehyde by rp-hplc coupled with electrochemical detector in serum samples. J Liq Chromatogr. 2015;38:1052-60.
32. Khan A, Khan MI, Iqbal Z, Shah Y, Ahmad L, Watson DG. An optimized and validated RP-HPLC/UVDetection method for simultaneous determination of all-trans-Retinol (Vitamin A) and a-Tocopherol (Vitamin E) in human serum: comparison of different particular reversed-phase HPLC columns. J Chromatogr. B. 2010;878(25):2339–47.
33. Mikstaclia R, Rimando AM, Ignatowicz E. Antioxidant effect of trans-reveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant Food Hum Nutr. 2010;65(1):57–63.
34. Adams LB. Hyperlipidemia. Guidelines for Adolescent Nutrition Services (2005). 2005. p. 109–24.
35. Kamada C, da Silva EL, Ohsishi-Kameyama M, Moon JH, Terao J. Attenuation of lipid peroxidation and hyperlipidemia by quercetin glucoside in the aorta of high cholesterol-fed rabbit. Free Radical Res. 2005;39(2):185–94.
36. Karuppaguonder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem Int. 2009;54(2):111–8.
37. Sahalkakkannan N, Rukumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative effects of curcumin and an analogue of curcumin in carbon tetrachloride-induced hepatotoxicity in rats. Basic Clin Pharmacol. 2005;9(7):15–21.
38. Choi CS, Chung HK, Choi MK, Kang MH. Effects of grape pomace on the antioxidant defense system in diet-induced hypercholesterolemic rabbits. Nutr Res Pract. 2010;4(2):114–20.
39. Gendelar A. Dual effect of curcumin in preventing atherosclerosis: the potential role of pro-oxidant–antioxidant mechanisms. Nat Prod Res. 2015; 29(6):491–2.
40. Cirico TL, Omaye ST. Additive or synergetic effects of phenolic compounds on human low density lipoprotein oxidation. Food Chem Toxicol. 2006; 44(4):510–6.
51. Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am J Clin Nutr. 2003;78(3):517S–20S.

52. Margalef M, Guerrero L, Pons Z, Bravo FI, Arola L, Muguerza B, et al. Low-molecular procyanidin rich grape seed extract exerts antihypertensive effect in males spontaneously hypertensive rats. Therapie. 2006;61(4):347–55.

53. Ruiz M, Fernandez M, Pico Y, Manes J, Asensi M, Carda C, et al. Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J Agr Food Chem. 2009;57(8):3180–6.

54. Zambon A, Zhao XQ, Brown BG, Brunzell JD. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol. 2014;113(9):1494–8.

55. Indumathi U, Kanchana K, Sachdanandam P. Protective role of coenzyme Q10, riboflavin, niacin, selenium (CoRNS) and Emblica officinalis on cardiac abnormalities in experimental atherosclerosis. Biomed Prev Nutr. 2013;3(4):313–8.

56. Lukasova M, Hanso J, Sunar S, Offermanns S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol Sci. 2011;32(12):700–7.

57. Basu TK, Mahani N, Sedgwick G. Niacin (nicotinic acid) in non-physiological doses causes hyperhomocystinaemia in Sprague–Dawley rats. Br J Nutr. 2002;87(02):115–9.

58. El-Aby AT, Ahmed AA, Fatani AJ. Protective effect of red grape seeds proanthocyanidins against induction of diabetes by alloxan in rats. Pharmaco Res. 2005;52(3):264–70.

59. Javed I, Zia-Ur-Rahman N, Khan MZ, Muhammad F, Aslam B, Iqbal Z, et al. Antihyperlipidemic efficacy of Trachyspermum ammi in albino rabbits. Acta Vet Brno. 2009;79(2):229–36.